In the fight against lung cancer, time is the most critical variable. For patients in the Provence-Alpes-Côte d’Azur (PACA) region, a systemic shift in how they enter the healthcare system is aiming to turn the tide on late-stage diagnoses and fragmented care.
The Centre Hospitalier Intercommunal Toulon – La Seyne (CHITS) has recently been awarded the label of « Filière remarquable dans la prise en charge du cancer du poumon » (Remarkable Pathway for Lung Cancer Care) by the Agence Régionale de Santé (ARS) PACA. This designation places the facility among only six centers of excellence in the region specifically recognized for their ability to accelerate the transition from initial suspicion to active treatment.
For many patients, the path to a diagnosis is often a gauntlet of waiting rooms and administrative hurdles. Historically, those fearing a malignancy often viewed the emergency room as their fastest route to care—a misconception that frequently leads to delays in specialized oncology consultation and an increase in patient stress. The new model at CHITS is designed to bypass this bottleneck entirely, replacing emergency room anxiety with a streamlined, direct-access system.
The initiative, described by medical leadership as an organization « au cordeau » (meticulously organized), focuses on removing the “mental load” from patients during one of the most vulnerable moments of their lives. By centralizing coordination, the hospital aims to ensure that no patient loses a critical window of opportunity for early intervention.
A direct line to specialized care
The cornerstone of this recognized pathway is a simplified entry point. Rather than navigating complex referral loops or waiting for emergency triage, patients and their primary care physicians can now initiate the diagnostic process through a single point of contact.
Dr. Clarisse Audigier-Valette, an onco-pneumologist at CHITS and the Centre anticancer Antoine Lacassagne in Nice, emphasizes that visibility is the primary barrier in non-university hospitals. « Longtemps, patients et médecins traitants ont pensé que se présenter aux urgences était la meilleure solution en cas de suspicion de cancer. Notre objectif est d’éviter ces arrivées aux Urgences et les pertes de chances liées à une prise en charge trop tardive, » Dr. Audigier-Valette explains.
The “remarkable” label was granted following an ARS call for projects, which provided the funding necessary to recruit dedicated administrative staff and a coordinating nurse. This structure mirrors the high-efficiency models found in major cancer centers, where the goal is to move the patient from suspicion to a diagnostic plan in days, not weeks.
Under this new protocol, once a case is identified as a suspected malignancy, the coordination secretariat reviews the file and proposes an appointment within seven days. Beyond the initial visit, the coordinating team manages the scheduling of essential diagnostic imaging, including MRIs and PET scans (TEP-Scan), ensuring the patient does not have to manage the logistical burden of multiple appointments whereas facing a potential cancer diagnosis.
Bridging the gap in clinical research
In addition to its organizational efficiency, CHITS received a special mention for its commitment to clinical research. This integration of research into a community hospital setting is designed to provide patients with access to cutting-edge therapeutic innovations that are typically reserved for large university research centers.
The hospital has created what Dr. Audigier-Valette describes as a “virtuous circle”: increased participation in clinical trials elevates the hospital’s overall expertise, which in turn attracts more innovative trials and benefits more patients.
The data highlights a significant departure from national benchmarks. While the Institut National du Cancer (INCa) sets a target inclusion rate of 10% for patients in therapeutic trials, CHITS has reached a rate of 25%. This means one in four patients at the facility has access to experimental treatments that could potentially offer better outcomes than standard care.
The public health urgency in PACA
The push for a “remarkable pathway” is driven by sobering statistics. Lung cancer remains the leading cause of cancer-related deaths in France, claiming approximately 33,100 lives annually. The situation is particularly acute in the PACA region, where nearly 3,500 new cases are diagnosed each year.
Data indicates a 10% higher incidence of lung cancer in PACA compared to the national average, with particularly high rates observed in the Var and Alpes-Maritimes departments. Most concerning is the stage of detection: 84% of these cancers are diagnosed at an advanced stage, when treatment options are more limited and prognosis is poorer.
| Metric | France (National) | PACA Region |
|---|---|---|
| Annual Deaths | ~33,100 | Not specified |
| Annual New Cases | National Average | ~3,500 |
| Incidence Rate | Baseline | 10% above average |
| Advanced Stage Diagnosis | High | 84% |
To ensure this new system reaches those who need it, CHITS has integrated the coordination contact details into all correspondence sent to primary care physicians, radiologists, and patients. The dedicated coordination line is 04.94.14.56.10.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients suspected of having a medical condition should consult a licensed healthcare provider immediately.
As the hospital continues to refine this pathway, the next phase focuses on maintaining the high trial inclusion rate and expanding the visibility of the coordination service among rural practitioners in the Var. Official updates on regional cancer care benchmarks are expected in the next annual ARS health report.
Do you believe streamlined coordination should be the standard for all cancer care? Share your thoughts in the comments or share this article with others who may benefit from this information.
